# OnCo record nct05824975 (trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/trials/nct05824975/>
  a schema:MedicalTrial ;
  onco:kind "trial" ;
  schema:identifier "nct05824975", "NCT05824975" ;
  schema:name "A Study to Evaluate the Safety and Therapeutic Activity of GI-102 As a Single Agent and in Combination with Conventional Anti-cancer Drugs, Pembrolizu"@en ;
  schema:alternateName "KEYNOTE-G08"@en ;
  schema:description "A phase 1/2 trial of Doxorubicin, Paclitaxel / nab-paclitaxel, Bevacizumab in sarcomas and ovarian cancer, run by GI Innovation, Inc., now recruiting."@en ;
  schema:url <https://onco.cc/trials/nct05824975/> ;
  schema:dateModified "2026-09-16"^^xsd:date ;
  schema:citation <https://clinicaltrials.gov/study/NCT05824975> ;
  onco:status "recruiting" ;
  onco:tag "ctgov-ingest" ;
  onco:phase "1/2" ;
  schema:startDate "2023-05-30" ;
  onco:cancers <https://onco.cc/cancers/sarcoma/>, <https://onco.cc/cancers/ovarian/>, <https://onco.cc/cancers/hcc/>, <https://onco.cc/cancers/colorectal/>, <https://onco.cc/cancers/melanoma/> ;
  onco:technologies <https://onco.cc/technologies/adc/>, <https://onco.cc/technologies/checkpoint-inhibitor/>, <https://onco.cc/technologies/topoisomerase-inhibitors/> ;
  onco:drugs <https://onco.cc/drugs/doxorubicin/>, <https://onco.cc/drugs/paclitaxel/>, <https://onco.cc/drugs/bevacizumab/>, <https://onco.cc/drugs/eribulin/>, <https://onco.cc/drugs/trastuzumab-deruxtecan/>, <https://onco.cc/drugs/pembrolizumab/> ;
  onco:companies <https://onco.cc/companies/gi-innovation/> .